EXAS vs. VTRS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at EXAS and VTRS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | EXAS | VTRS |
|---|---|---|
| Company Name | Exact Sciences Corporation | Viatris Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Biotechnology | Pharmaceuticals |
| Market Capitalization | 11.23 billion USD | 11.62 billion USD |
| Exchange | NasdaqCM | NasdaqGS |
| Listing Date | February 1, 2001 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of EXAS and VTRS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | EXAS | VTRS |
|---|---|---|
| 5-Day Price Return | 5.57% | -1.38% |
| 13-Week Price Return | 7.25% | 8.02% |
| 26-Week Price Return | 33.97% | 22.18% |
| 52-Week Price Return | -14.34% | -12.00% |
| Month-to-Date Return | 8.43% | 0.71% |
| Year-to-Date Return | 5.57% | -19.92% |
| 10-Day Avg. Volume | 2.07M | 7.61M |
| 3-Month Avg. Volume | 2.89M | 10.24M |
| 3-Month Volatility | 41.21% | 30.32% |
| Beta | 1.44 | 0.84 |
Profitability
Return on Equity (TTM)
EXAS
-38.37%
Biotechnology Industry
- Max
- 97.92%
- Q3
- 11.99%
- Median
- -19.30%
- Q1
- -51.29%
- Min
- -132.03%
EXAS has a negative Return on Equity of -38.37%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
VTRS
-19.92%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.85%
- Q1
- 5.40%
- Min
- -10.91%
VTRS has a negative Return on Equity of -19.92%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
EXAS
-34.19%
Biotechnology Industry
- Max
- 73.34%
- Q3
- 18.98%
- Median
- -12.96%
- Q1
- -105.72%
- Min
- -259.82%
EXAS has a negative Net Profit Margin of -34.19%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
VTRS
-24.57%
Pharmaceuticals Industry
- Max
- 40.67%
- Q3
- 19.07%
- Median
- 12.31%
- Q1
- 4.50%
- Min
- -9.91%
VTRS has a negative Net Profit Margin of -24.57%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
EXAS
-34.49%
Biotechnology Industry
- Max
- 78.85%
- Q3
- 21.90%
- Median
- -13.30%
- Q1
- -109.94%
- Min
- -278.10%
EXAS has a negative Operating Profit Margin of -34.49%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
VTRS
-26.54%
Pharmaceuticals Industry
- Max
- 45.78%
- Q3
- 23.14%
- Median
- 16.68%
- Q1
- 7.98%
- Min
- -7.13%
VTRS has a negative Operating Profit Margin of -26.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | EXAS | VTRS |
|---|---|---|
| Return on Equity (TTM) | -38.37% | -19.92% |
| Return on Assets (TTM) | -16.63% | -8.50% |
| Net Profit Margin (TTM) | -34.19% | -24.57% |
| Operating Profit Margin (TTM) | -34.49% | -26.54% |
| Gross Profit Margin (TTM) | 68.19% | 40.15% |
Financial Strength
Current Ratio (MRQ)
EXAS
2.89
Biotechnology Industry
- Max
- 16.97
- Q3
- 8.39
- Median
- 4.11
- Q1
- 2.64
- Min
- 0.74
EXAS’s Current Ratio of 2.89 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.
VTRS
1.37
Pharmaceuticals Industry
- Max
- 4.65
- Q3
- 2.64
- Median
- 1.85
- Q1
- 1.26
- Min
- 0.78
VTRS’s Current Ratio of 1.37 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
EXAS
0.95
Biotechnology Industry
- Max
- 1.92
- Q3
- 0.79
- Median
- 0.12
- Q1
- 0.00
- Min
- 0.00
EXAS’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 0.95. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
VTRS
0.82
Pharmaceuticals Industry
- Max
- 1.75
- Q3
- 0.82
- Median
- 0.35
- Q1
- 0.13
- Min
- 0.00
VTRS’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 0.82. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
EXAS
-15.18
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.03
- Median
- -9.59
- Q1
- -65.05
- Min
- -163.11
EXAS has a negative Interest Coverage Ratio of -15.18. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
VTRS
-0.13
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 43.60
- Median
- 9.83
- Q1
- 2.37
- Min
- -42.71
VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | EXAS | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 2.89 | 1.37 |
| Quick Ratio (MRQ) | 2.32 | 0.65 |
| Debt-to-Equity Ratio (MRQ) | 0.95 | 0.82 |
| Interest Coverage Ratio (TTM) | -15.18 | -0.13 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
VTRS
4.90%
Pharmaceuticals Industry
- Max
- 7.14%
- Q3
- 3.45%
- Median
- 2.17%
- Q1
- 0.33%
- Min
- 0.00%
With a Dividend Yield of 4.90%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
EXAS
0.00%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
EXAS has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
VTRS
137.04%
Pharmaceuticals Industry
- Max
- 199.58%
- Q3
- 97.17%
- Median
- 53.47%
- Q1
- 22.97%
- Min
- 0.00%
VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | EXAS | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 4.90% |
| Dividend Payout Ratio (TTM) | 0.00% | 137.04% |
Valuation
Price-to-Earnings Ratio (TTM)
EXAS
--
Biotechnology Industry
- Max
- 40.44
- Q3
- 39.37
- Median
- 22.12
- Q1
- 15.76
- Min
- 3.48
P/E Ratio data for EXAS is currently unavailable.
VTRS
--
Pharmaceuticals Industry
- Max
- 45.19
- Q3
- 27.91
- Median
- 20.59
- Q1
- 15.08
- Min
- 3.79
P/E Ratio data for VTRS is currently unavailable.
Price-to-Sales Ratio (TTM)
EXAS
3.77
Biotechnology Industry
- Max
- 92.67
- Q3
- 41.36
- Median
- 8.45
- Q1
- 4.46
- Min
- 0.97
In the lower quartile for the Biotechnology industry, EXAS’s P/S Ratio of 3.77 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
VTRS
0.82
Pharmaceuticals Industry
- Max
- 8.87
- Q3
- 4.56
- Median
- 2.14
- Q1
- 1.58
- Min
- 0.11
In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.82 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
EXAS
4.06
Biotechnology Industry
- Max
- 22.72
- Q3
- 10.68
- Median
- 4.55
- Q1
- 2.44
- Min
- 0.59
EXAS’s P/B Ratio of 4.06 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
VTRS
0.67
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.99
- Median
- 2.48
- Q1
- 1.53
- Min
- 0.59
VTRS’s P/B Ratio of 0.67 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | EXAS | VTRS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | -- | -- |
| Price-to-Sales Ratio (TTM) | 3.77 | 0.82 |
| Price-to-Book Ratio (MRQ) | 4.06 | 0.67 |
| Price-to-Free Cash Flow Ratio (TTM) | 88.58 | 6.81 |